180 related articles for article (PubMed ID: 8501150)
1. Biochemical assessment of bone formation and resorption in acromegaly.
Ezzat S; Melmed S; Endres D; Eyre DR; Singer FR
J Clin Endocrinol Metab; 1993 Jun; 76(6):1452-7. PubMed ID: 8501150
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
3. Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly.
Bolanowski M; Jedrzejuk D; Milewicz A; Arkowska A
Osteoporos Int; 2002; 13(4):303-8. PubMed ID: 12030545
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.
Ghiron LJ; Thompson JL; Holloway L; Hintz RL; Butterfield GE; Hoffman AR; Marcus R
J Bone Miner Res; 1995 Dec; 10(12):1844-52. PubMed ID: 8619364
[TBL] [Abstract][Full Text] [Related]
5. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients.
Scillitani A; Chiodini I; Carnevale V; Giannatempo GM; Frusciante V; Villella M; Pileri M; Guglielmi G; Di Giorgio A; Modoni S; Fusilli S; Di Cerbo A; Liuzzi A
J Bone Miner Res; 1997 Oct; 12(10):1729-36. PubMed ID: 9333135
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.
Legovini P; De Menis E; Breda F; Billeci D; Carteri A; Pavan P; Conte N
J Endocrinol Invest; 1997 Sep; 20(8):434-8. PubMed ID: 9364245
[TBL] [Abstract][Full Text] [Related]
7. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
[TBL] [Abstract][Full Text] [Related]
8. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients.
Ueland T; Fougner SL; Godang K; Schreiner T; Bollerslev J
Eur J Endocrinol; 2006 Nov; 155(5):709-15. PubMed ID: 17062887
[TBL] [Abstract][Full Text] [Related]
9. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
10. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
Zgliczynski W; Kochman M; Misiorowski W; Zdunowski P
Neuro Endocrinol Lett; 2007 Oct; 28(5):621-8. PubMed ID: 17984937
[TBL] [Abstract][Full Text] [Related]
11. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism.
Ahmad AM; Thomas J; Clewes A; Hopkins MT; Guzder R; Ibrahim H; Durham BH; Vora JP; Fraser WD
J Clin Endocrinol Metab; 2003 Jun; 88(6):2860-8. PubMed ID: 12788900
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density of the axial skeleton in acromegaly.
Ho PJ; Fig LM; Barkan AL; Shapiro B
J Nucl Med; 1992 Sep; 33(9):1608-12. PubMed ID: 1517833
[TBL] [Abstract][Full Text] [Related]
14. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity.
White HD; Ahmad AM; Durham BH; Chandran S; Patwala A; Fraser WD; Vora JP
J Clin Endocrinol Metab; 2006 Mar; 91(3):913-9. PubMed ID: 16352693
[TBL] [Abstract][Full Text] [Related]
15. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density and parameters of bone metabolism in patients with acromegaly.
Kotzmann H; Bernecker P; Hübsch P; Pietschmann P; Woloszczuk W; Svoboda T; Geyer G; Luger A
J Bone Miner Res; 1993 Apr; 8(4):459-65. PubMed ID: 8475795
[TBL] [Abstract][Full Text] [Related]
18. Gonadal status is an important determinant of bone density in acromegaly.
Lesse GP; Fraser WD; Farquharson R; Hipkin L; Vora JP
Clin Endocrinol (Oxf); 1998 Jan; 48(1):59-65. PubMed ID: 9509069
[TBL] [Abstract][Full Text] [Related]
19. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.
Hansen TB; Brixen K; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C
J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096
[TBL] [Abstract][Full Text] [Related]
20. Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines.
Street ME; Spaggiari C; Ziveri MA; Volta C; Federico G; Baroncelli GI; Bernasconi S; Saggese G
Horm Res; 2006; 66(4):162-8. PubMed ID: 16804317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
